UPPSALA,
The Transaction in brief
LIDDS acquires 100 percent of the shares inNoviga Research AB , which becomes a wholly owned subsidiary ofLIDDS AB . The purchase price consists of newly issued shares inLIDDS in a ratio of 1:1, which means that the number of shares inLIDDS after the transaction amounts to 136,463,326, a dilution of 50%.- The value of the transaction, based on
LIDDS ' average share price of0.238 SEK on 26 January, is approximately 16.2 MSEK. - All shareholders in Noviga are positive to the transaction and will unconditionally convert their shares in Noviga into shares in
LIDDS . - The acquisition is subject to approval by the general meeting of
LIDDS . The Board of Directors ofLIDDS will convene an Extraordinary General Meeting to be held on27 February 2024 .
Through the acquisition of Noviga,
"It is the Board's assessment that a diversification of
The financial effect of the proposed transaction is expected to have a limited impact on
Noviga Research's research team will continue to assist in the development of NOV202 and the company's other assets. The transaction is intended to be completed immediately following a resolution by the general meeting. The issue resolution is subject to the so-called Leo rules and a qualified majority is required for the resolution. For more information, see the notice convening the Extraordinary General Meeting.
[1] Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). A new type of drug that, with the help of an enzyme, prevents cancer cells from developing.
© Modular Finance, source